ABB India receives an Order to Automate Reliance Life Sciences' Biopharmaceutical Facilities

ABB India announced earlier this week that it had received a significant automation contract from Reliance Life Sciences (RLS) to automate its new manufacturing plants in Nashik. The order's value, however, was not disclosed by the company. Reliance Life Sciences (RLS) has awarded ABB India a major automation contract to automate its new manufacturing plants in Nashik, Maharashtra, according to a company statement. RLS's 160-acre Nashik facility will house plasma protein, biopharmaceutical, oncology pharmaceutical, and vaccine manufacturing plants.

Large-scale biotechnology manufacturing poses unique and complex process and automation challenges. To ensure product quality, these processes adhere to strict regulatory guidelines, and ABB's System 800xA solution reduces manufacturing errors and ensures high-quality yields. It communicates seamlessly with various skid systems and is widely used on the factory floor for seamless operator interaction, batch control, and production information.

"We are delighted to be working with Reliance Life Sciences on this critical project." This collaboration will strengthen our position in the pharma and life sciences market, where we see tremendous potential for growth and innovation as a technology provider," said G Balaji, SVP, Head of Energy Industries, ABB India. "Reliance Life Sciences has a tradition of leveraging automation technologies in its manufacturing processes as part of its larger objectives in quality and productivity," said Reliance Life Sciences President KV Subramaniam.